According to the Complaint, Centene Corporation describes itself as a leading healthcare enterprise that is committed to helping people live healthier lives. This class action was filed against Centene and two of its Officers.

During the Class Period, Defendants provided investors with material information concerning Centene’s expected revenue guidance and adjusted diluted EPS for fiscal year 2025. Defendants’ statements included, among other things, confidence in the Company’s enrollment and morbidity rates, as well as strong retention rates in Centene’s Medicare business.

The Complaint alleges that Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene’s enrollment and morbidity rates. The Complaint claims that such statements absent these material facts caused Plaintiff and other shareholders to purchase Centene’s securities at artificially inflated prices.